The Foundation Dedicated to Discovering a Cure for Neuroendocrine Cancer

Caring for Carcinoid Foundation

News

Syndicate content
04/03 Orphan Drug Designation for Gallium-68
The radiopharmaceutical Gallium-68 (DOTA0-hel-Tyr3) octreotide (Ga-68 DOTATOC) has been designated as an orphan drug by the US Food and Drug Administration (FDA) for the management of neuroendocrine tumors.
03/10 Exciting Collaboration with RCRF
The lack of widely available neuroendocrine cancer cell lines is a major obstacle to neuroendocrine cancer research.  Multiple cell lines that reliably recapitulate the behavior of neuroendocrine cancers are critically needed in order to move many necessary elements of carcinoid and neuroendocrine cancer research. 
01/17 Phase II CAPTEM Study Presented at ASCO GI Symposium

Robert L. Fine, MD presented encouraging results from a phase II clinical trial using a combination of temozolomide and capecitabine, or CAPTEM, in patients with various types of neuroendocrine tumors at the ASCO GI conference in San Francisco, CA yesterday.  

01/16 ASCO GI Symposium Reveals Latest in NET Research

The American Association of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium began today in San Francisco, California.

12/19 New "Research Results" Page Added to CFCF Website

Since 2005, the Caring for Carcinoid Foundation has awarded over $10 million in research grants to top scientists around the world.

11/04 Breaking News: Carcinoid Cancer Genome Project Published in Nature Genetics

Dr. Matthew Meyerson, MD, PhD, Associate Professor of Pathology at the Dana Farber Cancer Institute and Senior Associate Member of the Broad Institute, recently published the results of his research project identifying somatic mutations in the CDKN1B gene among patients with small intestine neuroendocrine tumors. Dr. Meyerson’s results could lead to new treatment strategies for patients with this mutation.

10/29 The MTH Young Investigator Award

The Caring for Carcinoid Foundation is excited to announce Peter Lewis PhD, as the recipient of the 2014 MTH Young Investigator award.

06/30 More Progress in Understanding Neuroendocrine Tumors from Johns Hopkins University

Scientists from Johns Hopkins University have uncovered more information about the genetics of pancreatic neuroendocrine tumors!

05/23 SUTENT Granted Approval for Treatment of Patients with Pancreatic Neuroendocrine Tumors

The US Food and Drug Administration (FDA) has granted approval to Pfizer, Inc. for SUTENT ® (sunitinib malate) to treat patients with pancreatic neuroendocrine tumors.

Get the facts on pancreatic neuroendocrine cancer

Make a Difference Get Involved Today

Sign-up for our e-Newsletter.

Tell Your Story

Sign-up for our e-Newsletter.

E-update Archive

video

Latest Video

Check out the CFCF video library.

Nancy

Ron's Blog

Read the latest blog from CFCF's Executive Director.

Nancy

Ron's Blog

Read the latest blog from CFCF's Executive Director.

Lauren

Lauren's Blog

Read the latest blog from CFCF's Director of Research.

Lauren

Lauren's Blog

Read the latest blog from CFCF's Director of Research.

video

Latest Video

Check out the CFCF video library.

Connect with CFCF online:
FacebookTwitterYouTube

Connect with CFCF online:
FacebookTwitterYouTube

Seal Exchange      

Seal Exchange